Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

17.45 -0.68 (-3.75%)

Streaming Delayed Price Updated: 10:29 AM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,022
Open	17.50
Bid (Size)	17.10 (100)
Ask (Size)	17.50 (200)
Prev. Close	18.13
Today's Range	17.45 - 17.50
52wk Range	13.30 - 20.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PureTech to Present at the Leerink Partners Global Healthcare Conference

Today 2:00 EST

From PureTech Health plc

Via Business Wire

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

February 19, 2026

From PureTech Health plc

Via Business Wire

Performance

YTD	+3.9%	+3.9%
1 Month	-8.4%	-8.4%
3 Month	+9.1%	+9.1%
6 Month	-11.1%	-11.1%
1 Year	-4.1%	-4.1%

More News

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From PureTech Health plc

Via Business Wire

PureTech Appoints Robert Lyne as Chief Executive Officer

December 18, 2025

From PureTech Health plc

Via Business Wire

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

December 08, 2025

From PureTech Health plc

Via Business Wire

PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

December 05, 2025

From PureTech Health plc

Via Business Wire

PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From PureTech Health plc

Via Business Wire

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

October 22, 2025

From PureTech Health plc

Via Business Wire

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

September 29, 2025

From PureTech Health plc

Via Business Wire

CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday ↗

September 19, 2025

Via Benzinga

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

September 11, 2025

From PureTech Health plc

Via Business Wire

PureTech (PRTC) Q2 2025 Earnings Call Transcript ↗

September 02, 2025

Via The Motley Fool

PureTech Health Cash Runway Extended ↗

September 02, 2025

Via The Motley Fool

Earnings Scheduled For August 28, 2025 ↗

August 28, 2025

Via Benzinga

PureTech Health plc – Half-Year Report

August 28, 2025

From PureTech Health plc

Via Business Wire

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

August 21, 2025

From PureTech Health plc

Via Business Wire

PureTech Health: Notice of Half-Yearly Results

August 18, 2025

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

August 13, 2025

From PureTech Health plc

Via Business Wire

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

August 12, 2025

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

July 17, 2025

From PureTech Health plc

Via Business Wire

PureTech Announces Leadership Transition

July 16, 2025

From PureTech Health plc

Via Business Wire

PureTech Announces Board Change

July 08, 2025

From PureTech Health plc

Via Business Wire

Why This Biotech Stock Just Doubled In A Single Day ↗

June 26, 2025

Via Benzinga

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement

June 26, 2025

From PureTech Health plc

Via Business Wire

PureTech Health: Results of Annual General Meeting

June 16, 2025

From PureTech Health plc

Via Business Wire

Frequently Asked Questions

Is PureTech Health plc - American Depositary Shares publicly traded?

Yes, PureTech Health plc - American Depositary Shares is publicly traded.

What exchange does PureTech Health plc - American Depositary Shares trade on?

PureTech Health plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for PureTech Health plc - American Depositary Shares?

The ticker symbol for PureTech Health plc - American Depositary Shares is PRTC on the Nasdaq Stock Market

What is the current price of PureTech Health plc - American Depositary Shares?

The current price of PureTech Health plc - American Depositary Shares is 17.45

When was PureTech Health plc - American Depositary Shares last traded?

The last trade of PureTech Health plc - American Depositary Shares was at 02/25/26 10:29 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.